Transferrin-conjugated SNALPs encapsulating 2′-O-methylated miR-34a for the treatment of multiple myeloma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Scognamiglio, Immacolata ^a   Di Martino, Maria Teresa ^b   Campani, Virginia ^a   Virgilio, Antonella ^a   Galeone, Aldo ^a   Gullà, Annamaria ^b   Gallo Cantafio, Maria Eugenia ^b   Misso, Gabriella ^c   Tagliaferri, Pierosandro ^b   Tassone, Pierfrancesco ^b   Caraglia, Michele ^c   De Rosa, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYLATED MICRORNA 34; ANTINEOPLASTIC AGENT; MICRORNA 34A; NANOCARRIER; STABLE NUCLEIC ACID LIPID VESICLE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; LIPID; LIPOSOME; MICRORNA; MIRN34 MICRORNA, HUMAN; NUCLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG FORMULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID VESICLE; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MOUSE; MULTIPLE MYELOMA; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PROTEIN EXPRESSION; SURFACE PROPERTY; WILD TYPE; ZETA POTENTIAL; ANIMAL; CELL PROLIFERATION; CHEMISTRY; FLOW CYTOMETRY; METABOLISM; METHYLATION; SCID MOUSE; STATIC ELECTRICITY;

ANIMALS; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; LIPIDS; MALE; METHYLATION; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; NUCLEIC ACIDS; PARTICLE SIZE; RECEPTORS, TRANSFERRIN; STATIC ELECTRICITY; TRANSFERRIN; UNILAMELLAR LIPOSOMES;

EID: 84896134590     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/217365     Document Type: Article

References (36)

1. Nana-Sinkam S. P., Croce C. M., Clinical applications for microRNAs in cancer. Clinical Pharmacology & Therapeutics 2013 93 98 104 10.1038/clpt.2012.192
2. Bader A. G., miR-34-a microRNA replacement therapy is headed to the clinic. Frontiers in Genetics 2012 3 article 120 10.3389/fgene.2012.00120
3. Prazeres D. M., Ferreira G. N., Monteiro G. A., Cooney C. L., Cabral J. M., Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. Trends in Biotechnology 1999 17 4 169 174 2-s2.0-0033120652 10.1016/S0167-7799(98)01291-8 (Pubitemid 29273948)
4. Akhtar S., Kole R., Juliano R. L., Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sciences 1991 49 24 1793 1801 2-s2.0-0026002671 10.1016/0024-3205(91)90480-Y
5. Budker V. G., Knorre D. G., Vlassov V. V., Cell membranes as barriers for antisense constructions. Antisense Research and Development 1992 2 2 177 184 2-s2.0-0026870924
6. Crooke R. M., In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 1991 6 6 609 646 2-s2.0-0026356572
7. Agrawal S., Zhang R., Pharmacokinetics of oligonucleotides. Ciba Foundation Symposium 1997 209 60 78 (Pubitemid 127781926)
8. Akhtar S., Agrawal S., In vivo studies with antisense oligonucleotides. Trends in Pharmacological Sciences 1997 18 1 12 18 2-s2.0-0031027349 10.1016/S0165-6147(96)01002-4 (Pubitemid 27072873)
9. Crooke S. T., Bennett C. F., Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology and Toxicology 1996 36 107 129 10.1146/annurev.pa.36.040196.000543 (Pubitemid 26168696)
10. Henry S. P., Giclas P. C., Leeds J., Pangburn M., Auletta C., Levin A. A., Kornbrust D. J., Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. Journal of Pharmacology and Experimental Therapeutics 1997 281 2 810 816 2-s2.0-0030922755 (Pubitemid 27203815)
11. De Rosa G., De Stefano D., Galeone A., Oligonucleotide delivery in cancer therapy. Expert Opinion on Drug Delivery 2010 7 11 1263 1278 2-s2.0-77958571036 10.1517/17425247.2010.527942
12. Holmlund J. T., Monia B. P., Kwoh T. J., Dorr F. A., Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Current Opinion in Molecular Therapeutics 1999 1 3 372 385 2-s2.0-0033065009 (Pubitemid 29309185)
13. De Rosa G., La Rotonda M. I., Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 2009 14 8 2801 2823 2-s2.0-69549097534 10.3390/molecules14082801
14. Hope M. J., Mui B., Ansell S., Ahkong Q. F., Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs. Molecular Membrane Biology 1998 15 1 1 14 2-s2.0-0031944899 (Pubitemid 28182079)
15. Zelphati O., Szoka F. C. Jr., Cationic liposomes as an oligonucleotide carrier: mechanism of action. Journal of Liposome Research 1997 7 1 31 49 2-s2.0-0031041090 (Pubitemid 27102510)
16. Smyth-Templeton N., Lasic D. D., Frederik P. M., Strey H. H., Roberts D. D., Pavlakis G. N., Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology 1997 15 7 647 652 2-s2.0-0030760143 (Pubitemid 27291165)
17. Semple S. C., Klimuk S. K., Harasym T. O., Dos Santos N., Ansell S. M., Wong K. F., Maurer N., Stark H., Cullis P. R., Hope M. J., Scherrer P., Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochimica et Biophysica Acta 2001 1510 1-2 152 166 2-s2.0-0035830624 10.1016/S0005-2736(00)00343-6 (Pubitemid 32149893)
18. Morrissey D. V., Lockridge J. A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C. S., Jeffs L. B., Judge A., MacLachlan I., Polisky B., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology 2005 23 8 1002 1007 2-s2.0-23444445660 10.1038/nbt1122 (Pubitemid 41114035)
19. Zimmermann T. S., Lee A. C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M. N., Harborth J., Heyes J. A., Jeffs L. B., John M., Judge A. D., Lam K., McClintock K., Nechev L. V., Palmer L. R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A. J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.-P., MacLachlan I., RNAi-mediated gene silencing in non-human primates. Nature 2006 441 111 114 2-s2.0-33646185371 10.1038/nature04688
20. Geisbert T. W., Lee A. C., Robbins M., Geisbert J. B., Honko A. N., Sood V., Johnson J. C., de Jong S., Tavakoli I., Judge A., Hensley L. E., Maclachlan I., Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. The Lancet 2010 375 9729 1896 1905 2-s2.0-77952680862 10.1016/S0140-6736(10)60357-1
21. + tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS ONE 2011 6 9 2-s2.0-80052632447 10.1371/journal.pone.0024584 e24584
22. Hermeking H., The miR-34 family in cancer and apoptosis. Cell Death and Differentiation 2010 17 2 193 199 2-s2.0-74249123570 10.1038/cdd.2009.56
23. Chang T.-C., Wentzel E. A., Kent O. A., Ramachandran K., Mullendore M., Lee K. H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C. J., Arking D., Beer M. A., Maitra A., Mendell J. T., Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular Cell 2007 26 5 745 752 2-s2.0-34249817549 10.1016/j.molcel.2007.05.010 (Pubitemid 46856245)
24. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., Hermeking H., Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007 6 13 1586 1593 2-s2.0-34250868124 (Pubitemid 47327945)
25. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M., Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell 2007 26 5 731 743 2-s2.0-34249822779 10.1016/j.molcel.2007.05.017 (Pubitemid 46856247)
26. Welch C., Chen Y., Stallings R. L., MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007 26 34 5017 5022 2-s2.0-34249812122 10.1038/sj.onc.1210293 (Pubitemid 47172643)
27. He L., He X., Lim L. P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A. L., Linsley P. S., Chen C., Lowe S. W., Cleary M. A., Hannon G. J., A microRNA component of the p53 tumour suppressor network. Nature 2007 447 7148 1130 1134 2-s2.0-34250851115 10.1038/nature05939 (Pubitemid 47014436)
28. Di Martino M. T., Leone E., Amodio N., Foresta U., Lionetti M., Pitari M. R., Cantafio M. E., Gullà A., Conforti F., Morelli E., Tomaino V., Rossi M., Negrini M., Ferrarini M., Caraglia M., Shammas M. A., Munshi N. C., Anderson K. C., Neri A., Tagliaferri P., Tassone P., Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clinical Cancer Research 2012 18 6260 6270 10.1158/1078-0432.CCR-12-1708
29. Stewart J. C., Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Analytical Biochemistry 1980 104 1 10 14 2-s2.0-0019304939 (Pubitemid 10045896)
30. Cotten M., Oberhauser B., Brunar H., Holzner A., Issakides G., Noe C. R., Schaffner G., Wagner E., Birnstiel M. L., 2′-O-methyl, 2′-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event. Nucleic Acids Research 1991 19 10 2629 2635 2-s2.0-0025825242 (Pubitemid 21896898)
31. Costa P. M., Cardoso A. L., Mendonça L. S., Serani A., Custódia C., Conceição M., Simões S., Moreira J. N., Pereira de Almeida L., Pedroso de Lima M. C., Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment. Molecular Therapy-Nucleic Acids 2013 2 article e100 10.1038/mtna.2013.30
32. Wilson C., Keefe A. D., Building oligonucleotide therapeutics using non-natural chemistries. Current Opinion in Chemical Biology 2006 10 6 607 614 10.1016/j.cbpa.2006.10.001 (Pubitemid 44821893)
33. Yeh C. J., Taylor C. G., Faulk W. P., Transferrin binding by peripheral blood mononuclear cells in human lymphomas, myelomas and leukemias. Vox Sanguinis 1984 46 4 217 223 2-s2.0-0021322337 (Pubitemid 14161547)
34. Kohgo Y., Nishisato T., Kondo H., Tsushima N., Niitsu Y., Urushizaki I., Circulating transferrin receptor in human serum. British Journal of Haematology 1986 64 2 277 281 (Pubitemid 16007294)
35. Ng P. P., Helguera G., Daniels T. R., Lomas S. Z., Rodriguez J. A., Schiller G., Bonavida B., Morrison S. L., Penichet M. L., Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 2006 108 8 2745 2754 2-s2.0-33750631022 10.1182/blood-2006-04-020263
36. Li L., Wang R., Wilcox D., Zhao X., Song J., Lin X., Kohlbrenner W. M., Fesik S. W., Shen Y., Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Therapy 2011 19 775 780 2-s2.0-80053352664 10.1038/gt.2011.146